Search results
Search for "oxidative stress" in Full Text gives 19 result(s) in Beilstein Journal of Organic Chemistry.
Research progress on the pharmacological activity, biosynthetic pathways, and biosynthesis of crocins
- Zhongwei Hua,
- Nan Liu and
- Xiaohui Yan
Beilstein J. Org. Chem. 2024, 20, 741–752, doi:10.3762/bjoc.20.68
- healthy and hypertensive rats depending on the dose [43]. In an angiotensin II-induced acute hypertension model, crocins could probably improve cardiovascular function by reducing the ROS level [44]. Chen et al. found that crocins could reduce inflammation and oxidative stress in the rat placenta and
Graphical Abstract
Figure 1: Principal structure of crocin and crocetin derivatives, including common substituents of the crocet...
Figure 2: The pharmacological activity and mechanisms of action of crocins.
Figure 3: Crocin biosynthetic pathways in C. sativus and G. jasminoides. Enzyme abbreviations are as follows:...
Green and sustainable approaches for the Friedel–Crafts reaction between aldehydes and indoles
- Periklis X. Kolagkis,
- Eirini M. Galathri and
- Christoforos G. Kokotos
Beilstein J. Org. Chem. 2024, 20, 379–426, doi:10.3762/bjoc.20.36
- cruciferous vegetables has also been showcased, due to the function of BIMs as oxidative stress inhibitors; however, the specific mechanism of action has yet to be determined [1][6]. This capability of BIMs to act as Nur77 antagonists, has resulted in their examination as potential anti-Parkinson’s disease
Graphical Abstract
Scheme 1: Examples of BIMs used for their medicinal properties.
Scheme 2: Mechanisms for the synthesis of BIMs using protic or Lewis acids as catalysts.
Scheme 3: Synthesis of bis(indolyl)methanes using DBDMH.
Scheme 4: Competition experiments and synthesis of bis(indolyl)methanes using DBDMH.
Scheme 5: Proposed mechanism for formation of BIM of using DBDMH.
Scheme 6: Synthesis of bis(indolyl)methanes using I2.
Scheme 7: General reaction mechanism upon halogen bonding.
Scheme 8: Synthesis of bis(indolyl)methanes using I2, introduced by Ji.
Scheme 9: Synthesis of bis(indolyl)methanes using Br2 in CH3CN.
Scheme 10: Βidentate halogen-bond donors.
Scheme 11: Synthesis of bis(indolyl)methanes using bidentate halogen-bond donor 26.
Scheme 12: Proposed reaction mechanism.
Scheme 13: Synthesis of bis(indolyl)methanes using iodoalkyne as catalyst.
Scheme 14: Proposed reaction mechanism.
Scheme 15: Optimized reaction conditions used by Ramshini.
Scheme 16: Activation of the carbonyl group by HPA/TPI-Fe3O4.
Scheme 17: Synthesis of BIMs in the presence of nanoAg-Pt/SiO2-doped silicate.
Scheme 18: Mechanism of action proposed by Khalafi-Nezhad et al.
Scheme 19: Activation of the carbonyl group by the Cu–isatin Schiff base complex.
Scheme 20: Optimum reaction conditions published by Jain.
Scheme 21: Organocatalytic protocol utilizing nanoparticles introduced by Bankar.
Scheme 22: Activation of the carbonyl group by the AlCl3·6H2O-SDS-SiO2 complex.
Scheme 23: Optimal reaction conditions for the aforementioned nano-Fe3O4 based catalysts.
Scheme 24: Nanocatalytic protocol proposed by Kaur et al.
Scheme 25: Microwave approach introduced by Yuan.
Scheme 26: Microwave approach introduced by Zahran et al.
Scheme 27: Microwave irradiation protocol introduced by Bindu.
Scheme 28: Silica-supported microwave irradiation protocol.
Scheme 29: Proposed mechanism for formation of BIM by Nongkhlaw.
Scheme 30: Microwave-assisted synthesis of BIMs catalyzed by succinic acid.
Scheme 31: Proposed mechanism of action of MMO-4.
Scheme 32: Catalytic approach introduced by Muhammadpoor-Baltork et al.
Scheme 33: Reaction conditions used by Xiao-Ming.
Scheme 34: Ultrasonic irradiation-based protocol published by Saeednia.
Scheme 35: Pyruvic acid-mediated synthesis of BIMs proposed by Thopate.
Scheme 36: Synthesis of BIMs using [bmim]BF4 or [bmim]PF6 ionic liquids.
Scheme 37: Synthesis of BIMs utilizing In(OTf)3 in octylmethylimidazolium hexafluorophosphate as ionic liquid.
Scheme 38: FeCl3·6H2O-catalyzed synthesis of BIMs with use of ionic liquid.
Scheme 39: Synthesis of BIMs utilizing the [hmim]HSO4/EtOH catalytic system.
Scheme 40: Synthesis of BIMs utilizing acidic ionic liquid immobilized on silica gel (ILIS-SO2Cl).
Scheme 41: The [bmim][MeSO4]-catalyzed reaction of indole with various aldehydes.
Scheme 42: The role of [bmim][MeSO4] in catalyzing the reaction of indole with aldehydes.
Scheme 43: Synthesis of BIMs utilizing FeCl3-based ionic liquid ([BTBAC]Cl-FeCl3) as catalyst.
Scheme 44: Synthesis of BIMs using [Msim]Cl at room temperature.
Scheme 45: [Et3NH][H2PO4]-catalyzed synthesis of bis(indolyl)methanes.
Scheme 46: PILs-catalyzed synthesis of bis(indolyl)methanes.
Scheme 47: FSILs-mediated synthesis of bis(indolyl)methanes.
Scheme 48: Possible “release and catch” catalytic process.
Scheme 49: Synthesis of bis(indolyl)methanes by [DABCO-H][HSO4].
Scheme 50: Synthesis of bis(indolyl)methanes by [(THA)(SO4)].
Scheme 51: Synthesis of BBSI-Cl and BBSI-HSO4.
Scheme 52: Synthesis of BIMs in the presence of BBSI-Cl and BBSI-HSO4.
Scheme 53: Chemoselectivity of the present method.
Scheme 54: Synthesis of BIMs catalyzed by chitosan-supported ionic liquid.
Scheme 55: Proposed mechanism of action of CSIL.
Scheme 56: Optimization of the reaction in DESs.
Scheme 57: Synthesis of BIMs using ChCl/SnCl2 as DES.
Scheme 58: Synthesis of BIMs derivatives in presence of DES.
Scheme 59: BIMs synthesis in choline chloride/urea (CC/U).
Scheme 60: Flow chemistry-based synthesis of BIMs by Ley.
Scheme 61: Flow chemistry-based synthesis of BIMs proposed by Nam et al.
Scheme 62: Amino-catalyzed reaction of indole with propionaldehyde.
Scheme 63: Aminocatalytic synthesis of BIMs.
Scheme 64: Proposed mechanism for the aminocatalytic synthesis of BIMs.
Scheme 65: Enzymatic reaction of indole with aldehydes.
Scheme 66: Proposed mechanism for the synthesis of BIMs catalyzed by TLIM.
Scheme 67: Proposed reaction mechanism by Badsara.
Scheme 68: Mechanism proposed by D’Auria.
Scheme 69: Photoinduced thiourea catalysis.
Scheme 70: Proposed mechanism of photoacid activation.
Scheme 71: Proposed mechanism of action for CF3SO2Na.
Scheme 72: Proposed mechanism for the synthesis of BIMs by Mandawad.
Scheme 73: Proposed mechanism for the (a) acid generation and (b) synthesis of BIMs.
Scheme 74: a) Reaction conditions employed by Khaksar and b) activation of the carbonyl group by HFIP.
Scheme 75: Activation of the carbonyl group by the PPy@CH2Br through the formation of a halogen bond.
Scheme 76: Reaction conditions utilized by Mhaldar et al.
Scheme 77: a) Reaction conditions employed by López and b) activation of the carbonyl group by thiourea.
Scheme 78: Infrared irradiation approach introduced by Luna-Mora and his research group.
Scheme 79: Synthesis of BIMs with the use of the Fe–Zn BMOF.
Effects of the aldehyde-derived ring substituent on the properties of two new bioinspired trimethoxybenzoylhydrazones: methyl vs nitro groups
- Dayanne Martins,
- Roberta Lamosa,
- Talis Uelisson da Silva,
- Carolina B. P. Ligiero,
- Sérgio de Paula Machado,
- Daphne S. Cukierman and
- Nicolás A. Rey
Beilstein J. Org. Chem. 2023, 19, 1713–1727, doi:10.3762/bjoc.19.125
- affect its pharmacological properties and metallophoric potential against copper(II) when compared to the unsubstituted counterpart. Nevertheless, the bioinspired compound was still able to reduce oxidative stress and affect the aggregation of the amyloid-β peptide, related to pathophysiological events
Graphical Abstract
Scheme 1: Structure of (A) 3-methylsalicylaldehyde 3,4,5-trimethoxybenzoyl hydrazone (hdz-CH3) and (B) 3-nitr...
Figure 1: ORTEP representation of the new N-acylhydrazones synthesized in the present work, drawn with therma...
Figure 2: (A) Superposition of molecular structures and stacked motifs of (B) hdz-CH3 and (C) hdz-NO2.
Figure 3: Overlap of the experimental (carbon atoms colored in gray) and theoretical structures (calculated w...
Figure 4: Mid-infrared spectra of the compounds. Experimental conditions: KBr pellets, room temperature. Calc...
Figure 5: 1H NMR (400 MHz) spectra of (A) hdz-CH3 and (B) hdz-NO2 in DMSO-d6 at 25 °C.
Figure 6: Electronic absorption spectra in a selected wavelength region for a solution of hdz-CH3 in 10% DMSO...
Figure 7: Electronic absorption spectra of hdz-NO2 in selected wavelength regions. Experimental conditions: l...
Scheme 2: General scheme for the synthesis of the studied hydrazones.
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
- (plasmalogen) is highly sensitive to oxidation and it is reported that this function is even more reactive than unsaturated and polyunsaturated lipid chains [27]. Accordingly, plasmalogens could act as ROS scavenger and thus protect tissues (e.g., brain) from oxidative stress. The replacement of an ester
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Phenanthridine–pyrene conjugates as fluorescent probes for DNA/RNA and an inactive mutant of dipeptidyl peptidase enzyme
- Josipa Matić,
- Tana Tandarić,
- Marijana Radić Stojković,
- Filip Šupljika,
- Zrinka Karačić,
- Ana Tomašić Paić,
- Lucija Horvat,
- Robert Vianello and
- Lidija-Marija Tumir
Beilstein J. Org. Chem. 2023, 19, 550–565, doi:10.3762/bjoc.19.40
- three amino acids. DPPIII participates in intracellular protein catabolism, which functions in pain modulation and oxidative stress. These biological functions make DPPIII a valuable target for drug development. Interestingly, although excimer emission was quenched, the pyrene monomer's emission was
Graphical Abstract
Scheme 1: Novel pyrene–phenanthridine conjugates Phen-Py-1 (longer, flexible linker) and Phen-Py-2 (shorter, ...
Scheme 2: Synthesis of Phen-Py-1 and Phen-Py-2 by amide formation; Reagents and conditions: 1. TFA–H2O mixtur...
Figure 1: 2D (left) and 3D (right) representation of fluorescence emission spectra of Phen-Py-1 (c = 2 × 10−6...
Figure 2: Most representative structures of the conjugates Phen-Py-1 and Phen-Py-2 at different pH conditions...
Figure 3: UV–vis titration of Phen-Py-1 with ct-DNA,; changes in the UV–vis spectra of Phen-Py-1 at λ = 350 n...
Figure 4: . Experimental (■) and calculated (–) (by Scatchard equation Table 2) fluorescence intensities of compound ...
Figure 5: Comparison of spectra of DNA-dye complex (r = 0.5, black) and sum of DNA and dye spectra (red) of a...
Figure 6: Fluorimetric titration of Phen-Py-1, λexc = 352 nm, c = 1 × 10−6 mol dm−3 with dipeptidyl peptidase...
Figure 7: A: ITC titration: raw titration data from the experimental injections of human DPP III enzyme mutan...
Photophysical, photostability, and ROS generation properties of new trifluoromethylated quinoline-phenol Schiff bases
- Inaiá O. Rocha,
- Yuri G. Kappenberg,
- Wilian C. Rosa,
- Clarissa P. Frizzo,
- Nilo Zanatta,
- Marcos A. P. Martins,
- Isadora Tisoco,
- Bernardo A. Iglesias and
- Helio G. Bonacorso
Beilstein J. Org. Chem. 2021, 17, 2799–2811, doi:10.3762/bjoc.17.191
- damage caused by oxidative stress, especially by eliminating reactive oxygen species (ROS) such as hydroxyl radicals (•OH), superoxide anions (O2•‒), and singlet oxygen (1O2) [3][22][23]. Therefore, research in recent years has focused on new compounds obtained from natural sources or by synthetic
- methods, which provide active ingredients to prevent or reduce the effects of oxidative stress in cells. Recently, our research group reported the synthesis of 6-amino-4-(trifluoromethyl)quinolines, which were obtained through an electrophilic aromatic substitution reaction catalyzed by sulfuric acid from
Graphical Abstract
Figure 1: Examples of structures and properties of Schiff bases of interest in the present study.
Scheme 1: General view for the present study.
Scheme 2: Synthesis of ((trifluoromethyl)quinolinyl)phenol Schiff bases 3aa–fa.
Scheme 3: Synthesis of trifluoromethylated quinolinyl-phenol Schiff bases 3bb–be.
Figure 2: ORTEP diagram of the crystal structure of (E)-2-(((2-phenyl-4-(trifluoromethyl)quinolin-6-yl)imino)...
Figure 3: Normalized absorption spectra in the UV–vis region of compounds (a) 3ea and (b) 3be in CHCl3, MeOH ...
Figure 4: Normalized steady-state fluorescence emission spectra of compound 3aa (R = Ph, R1 = H) in CHCl3 (bl...
Figure 5: Comparative normalized steady-state fluorescence emission spectra of compounds 3bb and 3be in the t...
Figure 6: Photostability (%) plots of derivatives 3aa–fa and 3bb–be in DMSO solution after irradiation with w...
Figure 7: DPBF photooxidation assays by red-light irradiation with diode laser (λ = 660 nm) in the presence o...
Synthesis and anticancer activity of bis(2-arylimidazo[1,2-a]pyridin-3-yl) selenides and diselenides: the copper-catalyzed tandem C–H selenation of 2-arylimidazo[1,2-a]pyridine with selenium
- Mio Matsumura,
- Tsutomu Takahashi,
- Hikari Yamauchi,
- Shunsuke Sakuma,
- Yukako Hayashi,
- Tadashi Hyodo,
- Tohru Obata,
- Kentaro Yamaguchi,
- Yasuyuki Fujiwara and
- Shuji Yasuike
Beilstein J. Org. Chem. 2020, 16, 1075–1083, doi:10.3762/bjoc.16.94
- variety of methods [14][15], and many of the targets exhibited biological activity (Figure 1). For example, bis(2-pyridyl) diselenide I has the potential to mitigate oxidative stress and inhibits the AChE activity [16], bis(quinolin-8-yl) diselenide (II) exhibited antioxidant activity in a skin cell model
Graphical Abstract
Figure 1: Biologically active selenides and diselenides having heteroaryl groups.
Figure 2: Ortep drawings of 2a (a and b) and 3a (c and d, thermal elipsoids indicate 50% probability).
Figure 3: The synthesis of bis(2-arylimidazopyridin-3-yl) diselenides. Reaction conditions: 1 (2 mmol), Se (2...
Figure 4: The synthesis of bis(2-arylimidazopyridin-3-yl) selenides. Reaction conditions: 1 (2 mmol), Se (1 m...
Scheme 1: Control reactions.
Scheme 2: Proposed mechanism (1).
Scheme 3: Proposed mechanism (2).
Figure 5: The cytotoxic effect of the bis(2-arylimidazo[1,2-a]pyridin-3-yl) diselenides 2 and selenides 3 on ...
Figure 6: The cytotoxic effect of the bis[2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl] diselenide 2f on can...
Figure 7: Cytotoxic effect of the bis[2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl] diselenide 2f on a cance...
The interaction between cucurbit[8]uril and baicalein and the effect on baicalein properties
- Xiaodong Zhang,
- Jun Xie,
- Zhiling Xu,
- Zhu Tao and
- Qianjun Zhang
Beilstein J. Org. Chem. 2020, 16, 71–77, doi:10.3762/bjoc.16.9
- has a strong activity to eliminate superoxide radicals in cell-free systems [25]. It is also considered as an anti-inflammatory agent [26][27] that generally protects against oxidative stress [28], more specifically in cardiac cells [29], and in cisplatin-induced acute kidney injury [30]. However
Graphical Abstract
Figure 1: Chemical structures of baicalein (left), cucurbit[8]uril (right).
Figure 2: The possible interaction model for Q[8] and baicalein.
Figure 3: 1H NMR spectra (400 MHz) of Q[8] (a), baicalein (b) and BALE–Q[8] (1:1) (c) recorded in DCl.
Figure 4: The absorption spectra of BALE upon the addition of Q[8] under different conditions [10 mol·L−1 HCl...
Figure 5: IR spectra of Q[8] (a), BALE (b), a physical mixture of Q[8]-BALE (NQ[8]/NBALE = 1:1) (c) and the B...
Figure 6: DTA spectra of BALE (a), Q[8] (b), a physical mixture Q[8]-BALE (NQ[8]/NBALE = 1:1) (c) and the BAL...
Figure 7: The stability curve of UV–vis absorption obtained for an isoconcentration of BALE and the BALE–Q[8]...
Figure 8: The phase solubility graph obtained for BALE in Q[8] at λ = 270 nm.
Figure 9: The clearance rate curve (A) and clearance time curve (B) of ABTS+· upon increasing the concentrati...
Figure 10: The release curves of BALE and BALE–Q[8].
Extension of the 5-alkynyluridine side chain via C–C-bond formation in modified organometallic nucleosides using the Nicholas reaction
- Renata Kaczmarek,
- Dariusz Korczyński,
- James R. Green and
- Roman Dembinski
Beilstein J. Org. Chem. 2020, 16, 1–8, doi:10.3762/bjoc.16.1
- HeLa and K562 cell lines [31]. The formation of a reactive oxygen species in the presence of cobalt compounds was determined in K562 cells. The results indicate that the mechanism of action for most antiproliferative cobalt compounds may be related to the induction of oxidative stress [31
Graphical Abstract
Scheme 1: Preparation of (2'-deoxy)-5-alkynyluridines 2 and 3, their dicobalt hexacarbonyl derivatives 4 and 5...
Figure 1: Structures of nucleosides 6 and 7, products of the Nicholas reaction.
Steroid diversification by multicomponent reactions
- Leslie Reguera,
- Cecilia I. Attorresi,
- Javier A. Ramírez and
- Daniel G. Rivera
Beilstein J. Org. Chem. 2019, 15, 1236–1256, doi:10.3762/bjoc.15.121
- yields. Overall, five different components are incorporated in the reaction sequence, whereas acid chlorides, anhydrides, hydrazine, etc., could also be employed in the post-MCR cyclization [44]. The library of steroidal heterocycles was tested against oxidative stress and neuroinflammation due to
Graphical Abstract
Figure 1: Structures of natural steroids of A) animal and B) plant origin.
Scheme 1: Synthesis of a steroidal β-lactam by Ugi reaction of a cholanic aldehyde [14].
Scheme 2: Synthetic route to steroidal 2,5-diketopiperazines based on a diastereoselective Ugi-4CR with an an...
Scheme 3: Multicomponent synthesis of a heterocycle–steroid hybrid using a ketosteroid as carbonyl component [18]....
Scheme 4: Synthesis of peptidomimetic–steroid hybrids using the Ugi-4CR with spirostanic amines and carboxyli...
Scheme 5: Synthesis of azasteroids using the Ugi-4CR with androstanic and pregnanic carboxylic acids [22].
Figure 2: Ugi-4CR-derived library of androstanic azasteroids with diverse substitution patterns at the phenyl...
Scheme 6: Synthesis of 4-azacholestanes by an intramolecular Ugi-4C-3R [26].
Scheme 7: Synthesis of amino acid–steroid hybrid by multiple Ugi-4CR using steroidal isocyanides [29].
Scheme 8: Synthesis of ecdysteroid derivatives by Ugi-4CR using a steroidal isocyanide [30].
Scheme 9: Stereoselective multicomponent synthesis of a steroid–tetrahydropyridine hybrid using a chiral bifu...
Scheme 10: Pd(II)-catalyzed three-component reaction with an alkynyl seco-cholestane [34].
Scheme 11: Multicomponent synthesis of steroid–thiazole hybrids from a steroidal ketone [36].
Scheme 12: Synthesis of cholanic pseudo-peptide derivatives by novel MCRs based on the reactivity of ynamide [37,38].
Scheme 13: Synthesis of steroid-fused pyrimidines and pyrimidones using the Biginelli-3CR [39,42,43].
Scheme 14: Synthesis of steroidal pyridopyrimidines by a reaction sequence comprising a 4CR followed by a post...
Scheme 15: Synthesis of steroid-fused pyrimidines by MCR of 2-hydroxymethylene-3-ketosteroids [46].
Scheme 16: Synthesis of steroid-fused naphthoquinolines by the Kozlov–Wang MCR using ketosteroids [50,51].
Scheme 17: Conjugation of steroids to carbohydrates and peptides by the Ugi-4CR [62,63].
Scheme 18: Solid-phase multicomponent conjugation of peptides to steroids by the Ugi-4CR [64].
Scheme 19: Solid-phase multicomponent conjugation of peptides to steroids by the Petasis-3CR [68].
Scheme 20: Synthesis of steroidal macrobicycles (cages) by multiple multicomponent macrocyclizations based on ...
Scheme 21: One-pot synthesis of steroidal cages by double Ugi-4CR-based macrocyclizations [76].
Photochemical generation of the 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical from caged nitroxides by near-infrared two-photon irradiation and its cytocidal effect on lung cancer cells
- Ayato Yamada,
- Manabu Abe,
- Yoshinobu Nishimura,
- Shoji Ishizaka,
- Masashi Namba,
- Taku Nakashima,
- Kiyofumi Shimoji and
- Noboru Hattori
Beilstein J. Org. Chem. 2019, 15, 863–873, doi:10.3762/bjoc.15.84
- approach for investigating the role of redox-active nitroxides in mediating oxidative stress in organisms [27][28][29][30][31][32]. In 1997, Scaiano and co-workers reported the triplet-xanthone sensitized generation of the 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical from alkoxyamine 1 under
- also observed (Figure 5). To evaluate whether the cytocidal effect was due to photochemical radical generation, cells exposed to 360 nm light for 1 min and the unexposed congeners were stained by using a ROS-ID oxidative stress detection kit (Enzo Life Sciences, Farmingdale, NY, U.S.A.). Reactive
- light using a fluorescence microscope (BIOREVO BZ-9000, Keyence, Osaka, Japan), intracellular ROS were detected using the ROS-ID Oxidative Stress Detection Kit (Enzo Life Sciences, Farmingdale, NY, USA) in conjunction with fluorescence microscopy. Intracellular ROS was detected in the form of green
Graphical Abstract
Scheme 1: Photochemical generation of TEMPO radical.
Scheme 2: Synthesis of caged nitroxides 2a and 2b.
Figure 1: Photochemical generation of TEMPO from 2a and 2b. EPR spectra acquired during the photolysis of 2a ...
Figure 2: Time profile for photochemical generation of TEMPO radical from 2 (5 mM) at ≈298 K in benzene: (a) ...
Scheme 3: Photochemical generation of TEMPO radical and photoproducts 6 and 7 under air atmosphere.
Figure 3: Time profile, ln([2a]/[2a]0) versus irradiation time, of two-photon uncaging reaction of TEMPO in t...
Figure 4: ESR spectra acquired during the photolysis of 2a (5 mM) in benzene using 365 nm light.
Scheme 4: Isodesmic reaction from BRa and 5b to 5a and BRb.
Figure 5: Irradiation time-dependent decline in viability of LLC cells with compound 2a.
Figure 6: Detection of intracellular ROS only in irradiated LLC cells with 2a-containing medium.
A chemoenzymatic synthesis of ceramide trafficking inhibitor HPA-12
- Seema V. Kanojia,
- Sucheta Chatterjee,
- Subrata Chattopadhyay and
- Dibakar Goswami
Beilstein J. Org. Chem. 2019, 15, 490–496, doi:10.3762/bjoc.15.42
- , suggesting the possibility of its use as an anticancer compound. Besides, inhibition of sphingolipid biosynthesis using HPA-12 has also been reported to inhibit hepatitis C virus replication substantially [4]. In another study, the CERT knockdown disrupted the normal oxidative stress response in Drosophila
Graphical Abstract
Figure 1: Structure of most active HPA-12 isomers, originally proposed (1) and revised (2).
Scheme 1: Lipase-catalyzed trans-acylation of (±)-4 and subsequent Mitsunobu inversion. Conditions: (i) Zn/TH...
Scheme 2: Synthesis of azide 9 from (S)-4. Conditions: (i) NaH/Bu4NI/BnBr/THF/25 °C/4 h; (ii) AD-mix-β/t-BuOH...
Scheme 3: Attempted synthesis of 2 from 9. Conditions: (i) (a) LiAlH4 (1 M in THF)/THF/25 °C/3 h, (b) DCC/DMA...
Scheme 4: Actual synthesis of 2 from 9. Conditions: (i) DDQ/CH2Cl2–H2O 4:1/3 h; (ii) a) LiAlH4/THF/25 °C/3 h,...
Investigation of the action of poly(ADP-ribose)-synthesising enzymes on NAD+ analogues
- Sarah Wallrodt,
- Edward L. Simpson and
- Andreas Marx
Beilstein J. Org. Chem. 2017, 13, 495–501, doi:10.3762/bjoc.13.49
- of ADP-ribosylation [3][4]. This posttranslational modification received considerable attention within the last decade [5][6] and has been linked to tumour biology, oxidative stress, inflammatory, and metabolic diseases [7]. Using NAD+ as a substrate, ARTDs covalently transfer ADP-riboses onto
Graphical Abstract
Figure 1: NAD+ is used as a substrate by ARTDs to form MARylated and PARylated proteins. Depicted are alkyne-...
Figure 2: Workflow of the ADP-ribosylation assay. The protein of interest (POI) is ADP-ribosylated by the res...
Figure 3: SDS PAGE analysis of ADP-ribosylation of histone H1.2 with ARTD1, ARTD2, ARTD5 and ARTD6 using NAD+...
Figure 4: SDS PAGE analysis of ADP-ribosylation of histone H1.2 with ARTD2, ARTD5 and ARTD 6 using NAD+ analo...
Inhibition of peptide aggregation by means of enzymatic phosphorylation
- Kristin Folmert,
- Malgorzata Broncel,
- Hans v. Berlepsch,
- Christopher H. Ullrich,
- Mary-Ann Siegert and
- Beate Koksch
Beilstein J. Org. Chem. 2016, 12, 2462–2470, doi:10.3762/bjoc.12.240
- the subject of numerous studies, the pathway of aggregation from soluble α-helical-rich or partially unfolded peptides into insoluble β-sheet-rich amyloid fibrils remains unclear. Several studies discovered parameters of peptide environment, like pH [12][13], oxidative stress [14], presence of organic
Graphical Abstract
Scheme 1: Helical wheel projection of two parallel helical strands and primary structure of KFM6. The recogni...
Figure 1: a) Time-dependent CD spectra and b) corresponding CD-minimum plot for random coil (black) and β-she...
Figure 2: ThT-binding assay of of 15 µM KFM6 in 50 mM Tris/HCl buffer with 10 mM MgCl2 at pH 7.5, 24 °C, and ...
Figure 3: a) TEM micrograph of 15 µM KFM6 in 50 mM Tris/HCl buffer with 10 mM MgCl2 at pH 7.5 and 24 °C. The ...
Figure 4: a) Enzymatic phosphorylation of 15 µM KFM6 in time-dependent CD-minimum plots. Addition of both 200...
Rearrangements of organic peroxides and related processes
- Ivan A. Yaremenko,
- Vera A. Vil’,
- Dmitry V. Demchuk and
- Alexander O. Terent’ev
Beilstein J. Org. Chem. 2016, 12, 1647–1748, doi:10.3762/bjoc.12.162
Graphical Abstract
Figure 1: The named transformations considered in this review.
Scheme 1: The Baeyer–Villiger oxidation.
Scheme 2: The general mechanism of the peracid-promoted Baeyer–Villiger oxidation.
Scheme 3: General mechanism of the Lewis acid-catalyzed Baeyer–Villiger rearrangement.
Scheme 4: The theoretically studied mechanism of the BV oxidation reaction promoted by H2O2 and the Lewis aci...
Scheme 5: Proton movements in the transition states of the Baeyer–Villiger oxidation.
Scheme 6: The dependence of the course of the Baeyer–Villiger oxidation on the type of O–O-bond cleavage in t...
Scheme 7: The acid-catalyzed Baeyer–Villiger oxidation of cyclic epoxy ketones 22.
Scheme 8: Oxidation of isophorone oxide 29.
Scheme 9: Synthesis of acyl phosphate 32 from acyl phosphonate 31.
Scheme 10: Synthesis of aflatoxin B2 (36).
Scheme 11: The Baeyer–Villiger rearrangement of ketones 37 to lactones 38.
Scheme 12: Synthesis of 3,4-dimethoxybenzoic acid (40) via Baeyer–Villiger oxidation.
Scheme 13: Oxone transforms α,β-unsaturated ketones 43 into vinyl acetates 44.
Scheme 14: The Baeyer–Villiger oxidation of ketones 45 using diaryl diselenide and hydrogen peroxide.
Scheme 15: Baeyer–Villiger oxidation of (E)-2-methylenecyclobutanones.
Scheme 16: Oxidation of β-ionone (56) by H2O2/(BnSe)2 with formation of (E)-2-(2,6,6-trimethylcyclohex-1-en-1-...
Scheme 17: The mechanism of oxidation of ketones 58a–f by hydrogen peroxide in the presence of arsonated polys...
Scheme 18: Oxidation of ketone (58b) by H2O2 to 6-methylcaprolactone (59b) catalyzed by Pt complex 66·BF4.
Scheme 19: Oxidation of ketones 67 with H2O2 in the presence of [(dppb}Pt(µ-OH)]22+.
Scheme 20: The mechanism of oxidation of ketones 67 in the presence of [(dppb}Pt(µ-OH)]22+ and H2O2.
Scheme 21: Oxidation of benzaldehydes 69 in the presence of the H2O2/MeReO3 system.
Scheme 22: Oxidation of acetophenones 72 in the presence of the H2O2/MeReO3 system.
Scheme 23: Baeyer–Villiger oxidation of 2-adamantanone (45c) in the presence of Sn-containing mesoporous silic...
Scheme 24: Aerobic Baeyer–Villiger oxidation of ketones 76 using metal-free carbon.
Scheme 25: A regioselective Baeyer-Villiger oxidation of functionalized cyclohexenones 78 into a dihydrooxepin...
Scheme 26: The oxidation of aldehydes and ketones 80 by H2O2 catalyzed by Co4HP2Mo15V3O62.
Scheme 27: The cleavage of ketones 82 with hydrogen peroxide in alkaline solution.
Scheme 28: Oxidation of ketones 85 to esters 86 with H2O2–urea in the presence of KHCO3.
Scheme 29: Mechanism of the asymmetric oxidation of cyclopentane-1,2-dione 87a with the Ti(OiPr)4/(+)DET/t-BuO...
Scheme 30: The oxidation of cis-4-tert-butyl-2-fluorocyclohexanone (93) with m-chloroperbenzoic acid.
Scheme 31: The mechanism of the asymmetric oxidation of 3-substituted cyclobutanone 96a in the presence of chi...
Scheme 32: Enantioselective Baeyer–Villiger oxidation of cyclic ketones 98.
Scheme 33: Regio- and enantioselective Baeyer–Villiger oxidation of cyclic ketones 101.
Scheme 34: The proposed mechanism of the Baeyer–Villiger oxidation of acetal 105f.
Scheme 35: Synthesis of hydroxy-10H-acridin-9-one 117 from tetramethoxyanthracene 114.
Scheme 36: The Baeyer–Villiger oxidation of the fully substituted pyrrole 120.
Scheme 37: The Criegee rearrangement.
Scheme 38: The mechanism of the Criegee reaction of a peracid with a tertiary alcohol 122.
Scheme 39: Criegee rearrangement of decaline ethylperoxoate 127 into ketal 128.
Scheme 40: The ionic cleavage of 2-methoxy-2-propyl perester 129.
Scheme 41: The Criegee rearrangement of α-methoxy hydroperoxide 136.
Scheme 42: Synthesis of enol esters and acetals via the Criegee rearrangement.
Scheme 43: Proposed mechanism of the transformation of 1-hydroperoxy-2-oxabicycloalkanones 147a–d.
Scheme 44: Transformation of 3-hydroxy-1,2-dioxolanes 151 into diketone derivatives 152.
Scheme 45: Criegee rearrangement of peroxide 153 with the mono-, di-, and tri-O-insertion.
Scheme 46: The sequential Criegee rearrangements of adamantanes 157a,b.
Scheme 47: Synthesis of diaryl carbonates 160a–d from triarylmethanols 159a–d through successive oxygen insert...
Scheme 48: The synthesis of sesquiterpenes 162 from ketone 161 with a Criegee rearrangement as one key step.
Scheme 49: Synthesis of trans-hydrindan derivatives 164, 165.
Scheme 50: The Hock rearrangement.
Scheme 51: The general scheme of the cumene process.
Scheme 52: The Hock rearrangement of aliphatic hydroperoxides.
Scheme 53: The mechanism of solvolysis of brosylates 174a–c and spiro cyclopropyl carbinols 175a–c in THF/H2O2....
Scheme 54: The fragmentation mechanism of hydroperoxy acetals 178 to esters 179.
Scheme 55: The acid-catalyzed rearrangement of phenylcyclopentyl hydroperoxide 181.
Scheme 56: The peroxidation of tertiary alcohols in the presence of a catalytic amount of acid.
Scheme 57: The acid-catalyzed reaction of bicyclic secondary alcohols 192 with hydrogen peroxide.
Scheme 58: The photooxidation of 5,6-disubstituted 3,4-dihydro-2H-pyrans 196.
Scheme 59: The oxidation of tertiary alcohols 200a–g, 203a,b, and 206.
Scheme 60: Transformation of functional peroxide 209 leading to 2,3-disubstitued furans 210 in one step.
Scheme 61: The synthesis of carbazoles 213 via peroxide rearrangement.
Scheme 62: The construction of C–N bonds using the Hock rearrangement.
Scheme 63: The synthesis of moiety 218 from 217 which is a structural motif in the antitumor–antibiotic of CC-...
Scheme 64: The in vivo oxidation steps of cholesterol (219) by singlet oxygen.
Scheme 65: The proposed mechanism of the rearrangement of cholesterol-5α-OOH 220.
Scheme 66: Photochemical route to artemisinin via Hock rearrangement of 223.
Scheme 67: The Kornblum–DeLaMare rearrangement.
Scheme 68: Kornblum–DeLaMare transformation of 1-phenylethyl tert-butyl peroxide (225).
Scheme 69: The synthesis 4-hydroxyenones 230 from peroxide 229.
Scheme 70: The Kornblum–DeLaMare rearrangement of peroxide 232.
Scheme 71: The reduction of peroxide 234.
Scheme 72: The Kornblum–DeLaMare rearrangement of endoperoxide 236.
Scheme 73: The rearrangement of peroxide 238 under Kornblum–DeLaMare conditions.
Scheme 74: The proposed mechanism of rearrangement of peroxide 238.
Scheme 75: The Kornblum–DeLaMare rearrangement of peroxides 242a,b.
Scheme 76: The base-catalyzed rearrangements of bicyclic endoperoxides having electron-withdrawing substituent...
Scheme 77: The base-catalyzed rearrangements of bicyclic endoperoxides 249a,b having electron-donating substit...
Scheme 78: The base-catalyzed rearrangements of bridge-head substituted bicyclic endoperoxides 251a,b.
Scheme 79: The Kornblum–DeLaMare rearrangement of hydroperoxide 253.
Scheme 80: Synthesis of β-hydroxy hydroperoxide 254 from endoperoxide 253.
Scheme 81: The amine-catalyzed rearrangement of bicyclic endoperoxide 263.
Scheme 82: The base-catalyzed rearrangement of meso-endoperoxide 268 into 269.
Scheme 83: The photooxidation of 271 and subsequent Kornblum–DeLaMare reaction.
Scheme 84: The Kornblum–DeLaMare rearrangement as one step in the oxidation reaction of enamines.
Scheme 85: The Kornblum–DeLaMare rearrangement of 3,5-dihydro-1,2-dioxenes 284, 1,2-dioxanes 286, and tert-but...
Scheme 86: The Kornblum–DeLaMare rearrangement of epoxy dioxanes 290a–d.
Scheme 87: Rearrangement of prostaglandin H2 292.
Scheme 88: The synthesis of epicoccin G (297).
Scheme 89: The Kornblum–DeLaMare rearrangement used in the synthesis of phomactin A.
Scheme 90: The Kornblum–DeLaMare rearrangement in the synthesis of 3H-quinazolin-4-one 303.
Scheme 91: The Kornblum–DeLaMare rearrangement in the synthesis of dolabriferol (308).
Scheme 92: Sequential transformation of 3-substituted 2-pyridones 309 into 3-hydroxypyridine-2,6-diones 311 in...
Scheme 93: The Kornblum–DeLaMare rearrangement of peroxide 312 into hydroxy enone 313.
Scheme 94: The Kornblum–DeLaMare rearrangement in the synthesis of polyfunctionalized carbonyl compounds 317.
Scheme 95: The Kornblum–DeLaMare rearrangement in the synthesis of (Z)-β-perfluoroalkylenaminones 320.
Scheme 96: The Kornblum–DeLaMare rearrangement in the synthesis of γ-ketoester 322.
Scheme 97: The Kornblum–DeLaMare rearrangement in the synthesis of diterpenoids 326 and 328.
Scheme 98: The synthesis of natural products hainanolidol (331) and harringtonolide (332) from peroxide 329.
Scheme 99: The synthesis of trans-fused butyrolactones 339 and 340.
Scheme 100: The synthesis of leucosceptroid C (343) and leucosceptroid P (344) via the Kornblum–DeLaMare rearra...
Scheme 101: The Dakin oxidation of arylaldehydes or acetophenones.
Scheme 102: The mechanism of the Dakin oxidation.
Scheme 103: A solvent-free Dakin reaction of aromatic aldehydes 356.
Scheme 104: The organocatalytic Dakin oxidation of electron-rich arylaldehydes 358.
Scheme 105: The Dakin oxidation of electron-rich arylaldehydes 361.
Scheme 106: The Dakin oxidation of arylaldehydes 358 in water extract of banana (WEB).
Scheme 107: A one-pot approach towards indolo[2,1-b]quinazolines 364 from indole-3-carbaldehydes 363 through th...
Scheme 108: The synthesis of phenols 367a–c from benzaldehydes 366a-c via acid-catalyzed Dakin oxidation.
Scheme 109: Possible transformation paths of the highly polarized boric acid coordinated H2O2–aldehyde adduct 3...
Scheme 110: The Elbs oxidation of phenols 375 to hydroquinones.
Scheme 111: The mechanism of the Elbs persulfate oxidation of phenols 375 affording p-hydroquinones 376.
Scheme 112: Oxidation of 2-pyridones 380 under Elbs persulfate oxidation conditions.
Scheme 113: Synthesis of 3-hydroxy-4-pyridone (384) via an Elbs oxidation of 4-pyridone (382).
Scheme 114: The Schenck rearrangement.
Scheme 115: The Smith rearrangement.
Scheme 116: Three main pathways of the Schenck rearrangement.
Scheme 117: The isomerization of hydroperoxides 388 and 389.
Scheme 118: Trapping of dioxacyclopentyl radical 392 by oxygen.
Scheme 119: The hypothetical mechanism of the Schenck rearrangement of peroxide 394.
Scheme 120: The autoxidation of oleic acid (397) with the use of labeled isotope 18O2.
Scheme 121: The rearrangement of 18O-labeled hydroperoxide 400 under an atmosphere of 16O2.
Scheme 122: The rearrangement of the oleate-derived allylic hydroperoxides (S)-421 and (R)-425.
Scheme 123: Mechanisms of Schenck and Smith rearrangements.
Scheme 124: The rearrangement and cyclization of 433.
Scheme 125: The Wieland rearrangement.
Scheme 126: The rearrangement of bis(triphenylsilyl) 439 or bis(triphenylgermyl) 441 peroxides.
Scheme 127: The oxidative transformation of cyclic ketones.
Scheme 128: The hydroxylation of cyclohexene (447) in the presence of tungstic acid.
Scheme 129: The oxidation of cyclohexene (447) under the action of hydrogen peroxide.
Scheme 130: The reaction of butenylacetylacetone 455 with hydrogen peroxide.
Scheme 131: The oxidation of bridged 1,2,4,5-tetraoxanes.
Scheme 132: The proposed mechanism for the oxidation of bridged 1,2,4,5-tetraoxanes.
Scheme 133: The rearrangement of ozonides.
Scheme 134: The acid-catalyzed oxidative rearrangement of malondialdehydes 462 under the action of H2O2.
Scheme 135: Pathways of the Lewis acid-catalyzed cleavage of dialkyl peroxides 465 and ozonides 466.
Scheme 136: The mechanism of the transformation of (tert-butyldioxy)cyclohexanedienones 472.
Scheme 137: The synthesis of Vitamin K3 from 472a.
Scheme 138: Proposed mechanism for the transformation of 478d into silylated endoperoxide 479d.
Scheme 139: The rearrangement of hydroperoxide 485 to form diketone 486.
Scheme 140: The base-catalyzed rearrangement of cyclic peroxides 488a–g.
Scheme 141: Synthesis of chiral epoxides and aldols from peroxy hemiketals 491.
Scheme 142: The multistep transformation of (R)-carvone (494) to endoperoxides 496a–e.
Scheme 143: The decomposition of anthracene endoperoxide 499.
Scheme 144: Synthesis of esters 503 from aldehydes 501 via rearrangement of peroxides 502.
Scheme 145: Two possible paths for the base-promoted decomposition of α-azidoperoxides 502.
Scheme 146: The Story decomposition of cyclic diperoxide 506a.
Scheme 147: The Story decomposition of cyclic triperoxide 506b.
Scheme 148: The thermal rearrangement of endoperoxides A into diepoxides B.
Scheme 149: The transformation of peroxide 510 in the synthesis of stemolide (511).
Scheme 150: The possible mechanism of the rearrangement of endoperoxide 261g.
Scheme 151: The photooxidation of indene 517.
Scheme 152: The isomerization of ascaridole (523).
Scheme 153: The isomerization of peroxide 525.
Scheme 154: The thermal transformation of endoperoxide 355.
Scheme 155: The photooxidation of cyclopentadiene (529) at a temperature higher than 0 °C.
Scheme 156: The thermal rearrangement of endoperoxides 538a,b.
Scheme 157: The transformation of peroxides 541.
Scheme 158: The thermal rearrangements of strained cyclic peroxides.
Scheme 159: The thermal rearrangement of diacyl peroxide 551 in the synthesis of C4-epi-lomaiviticin B core 553....
Scheme 160: The 1O2 oxidation of tryptophan (554) and rearrangement of dioxetane intermediate 555.
Scheme 161: The Fe(II)-promoted cleavage of aryl-substituted bicyclic peroxides.
Scheme 162: The proposed mechanism of the Fe(II)-promoted rearrangement of 557a–c.
Scheme 163: The reaction of dioxolane 563 with Fe(II) sulfate.
Scheme 164: Fe(II)-promoted rearrangement of 1,2-dioxane 565.
Scheme 165: Fe(II) cysteinate-promoted rearrangement of 1,2-dioxolane 568.
Scheme 166: The transformation of 1,2-dioxanes 572a–c under the action of FeCl2.
Scheme 167: Fe(II) cysteinate-promoted transformation of tetraoxane 574.
Scheme 168: The CoTPP-catalyzed transformation of bicyclic endoperoxides 600a–d.
Scheme 169: The CoTPP-catalyzed transformation of epoxy-1,2-dioxanes.
Scheme 170: The Ru(II)-catalyzed reactions of 1,4-endoperoxide 261g.
Scheme 171: The Ru(II)-catalyzed transformation as a key step in the synthesis of elyiapyrone A (610) from 1,4-...
Scheme 172: Peroxides with antimalarial activity.
Scheme 173: The interaction of iron ions with artemisinin (616).
Scheme 174: The interaction of FeCl2 with 1,2-dioxanes 623, 624.
Scheme 175: The mechanism of reaction 623 and 624 with Fe(II)Cl2.
Scheme 176: The reaction of bicyclic natural endoperoxides G3-factors 631–633 with FeSO4.
Scheme 177: The transformation of terpene cardamom peroxide 639.
Scheme 178: The different ways of the cleavage of tetraoxane 643.
Scheme 179: The LC–MS analysis of interaction of tetraoxane 646 with iron(II)heme 647.
Scheme 180: The rearrangement of 3,6-epidioxy-1,10-bisaboladiene (EDBD, 649).
Scheme 181: Easily oxidized substrates.
Scheme 182: Biopathway of synthesis of prostaglandins.
Scheme 183: The reduction and rearrangements of isoprostanes.
Scheme 184: The partial mechanism for linoleate 658 oxidation.
Scheme 185: The transformation of lipid hydroperoxide.
Scheme 186: The acid-catalyzed cleavage of the product from free-radical oxidation of cholesterol (667).
Scheme 187: Two pathways of catechols oxidation.
Scheme 188: Criegee-like or Hock-like rearrangement of the intermediate hydroperoxide 675 in dioxygenase enzyme...
Scheme 189: Carotinoides 679 cleavage by carotenoid cleavage dioxygenases.
Antibiotics from predatory bacteria
- Juliane Korp,
- María S. Vela Gurovic and
- Markus Nett
Beilstein J. Org. Chem. 2016, 12, 594–607, doi:10.3762/bjoc.12.58
- possess antioxidative properties and might thus confer resistance towards oxidative stress [63]. Structurally, the DKxanthenes harbor a hydrophilic asparagine moiety attached to a hydrophobic polyene chain bearing an additional oxazoline and pyrrol ring system. Their production seems to be universal among
Graphical Abstract
Figure 1: Natural products isolated from M. xanthus DK1622. DKxanthene-534 (1); myxalamid B (2); myxovirescin...
Figure 2: Vegetative cells of P. fallax HKI 727 under a phase-contrast microscope (K. Martin, unpublished). B...
Figure 3: Structures of myxopyronins A (11) and B (12), corallopyronins A (13), B (14) and C (15), as well as...
Figure 4: Structure of althiomycin (17).
Figure 5: Structures of cystobactamids 919-1 (18), 919-2 (19), and 507 (20).
Figure 6: Structures of natural products isolated from Herpetosiphon spp.: siphonazole (21); auriculamide (22...
Interactions between 4-thiothymidine and water-soluble cyclodextrins: Evidence for supramolecular structures in aqueous solutions
- Vito Rizzi,
- Sergio Matera,
- Paola Semeraro,
- Paola Fini and
- Pinalysa Cosma
Beilstein J. Org. Chem. 2016, 12, 549–563, doi:10.3762/bjoc.12.54
- degradative ROS-mediated oxidation process [26]. Recently, in our papers [26], we have shown the pH-related features and the photoactivity of S4TdR in aqueous solution while simultaneously elucidating the nature of products induced by light-stimulated oxidative stress. Evidence for the generation of thymidine
Graphical Abstract
Figure 1: Molecular structure of S4TdR. H atoms are also labeled in the Figure.
Figure 2: Comparison between UV–vis absorption spectra (detailed view: 280–380 nm) obtained for 1 × 10−5 M aq...
Figure 3: Cyclic voltammetry of aqueous solutions containing S4TdR (black solid line) in presence of increasi...
Figure 4: (A) Plot of cathodic potential values and (B) of the corresponding current intensity, obtained for S...
Figure 5: Comparison between detailed views (frequency range: 4000–600 cm−1) of the FTIR–ATR spectra obtained...
Figure 6: Modified Benesi–Hildebrand plot of [H]/[G]/Δδ versus [H]/[G] in the presence of S4TdR at an initial...
Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
- Todd J. Eckroat,
- Abdelrahman S. Mayhoub and
- Sylvie Garneau-Tsodikova
Beilstein J. Org. Chem. 2013, 9, 1012–1044, doi:10.3762/bjoc.9.116
- neurons and acetylcholine (ACh) levels, plaques caused by aggregation of the protein fragment amyloid-β (Aβ), tangles associated with irregular phosphorylation of tau protein, inflammation and increased oxidative stress from reactive oxygen species (ROS), as well as dyshomeostasis and
Graphical Abstract
Figure 1: Structures of A. dyes originally used to stain Aβ and B. newer scaffolds explored for the developme...
Scheme 1: General synthetic strategies (Gs) used to introduce A. 18F, B. 11C, C. 99mTc/Re, and D. 123I and 125...
Scheme 2: A. Structures of radiolabeled chalcone analogues discussed. B.–D. Synthetic schemes for the prepara...
Scheme 3: A. Structures of the radiolabeled flavone and aurone analogues discussed. B. Synthetic scheme for t...
Scheme 4: A. Structures of the radiolabeled stilbene analogues discussed. B. Synthetic scheme for the prepara...
Scheme 5: A. Structures of the diphenyl-1,3,4- and diphenyl-1,2,4-oxadiazoles discussed. B.,C. Synthetic sche...
Figure 2: Structures of the radiolabeled benzothiazole analogues discussed.
Scheme 6: A.–F. Synthetic schemes for the preparation of [11C]56b, [11C]56c, 57, 58a,b, 61, and [18F]65a–d.
Scheme 7: A. Structures of the [Re]- and [99mTc]-labeled benzothiazole analogues discussed. B.,C. Synthetic s...
Figure 3: Structures of the radiolabeled benzoxazole analogues discussed.
Scheme 8: A.–E. Synthetic schemes for the preparation of 94, [123I]95e, 96–98.
Figure 4: Structures of the radiolabeled benzofuran analogues discussed.
Scheme 9: A.–E. Synthetic schemes for the preparation of 121, [125I]122a, 123a,b, 125a,b, and 126.
Scheme 10: A. Structures of the radiolabeled imidazopyridine analogues discussed. B. Synthetic scheme for the ...
Scheme 11: Synthetic scheme for the preparation of the benzimidazole 146.
Figure 5: Structures of the quinolines discussed.
Scheme 12: Synthetic scheme for the preparation of the naphthalene analogues 152 and 160a,b.
Scheme 13: A. Structures of the radiolabeled analogues resulting from the combination of various scaffolds. B.,...
Scheme 14: A.–C. Synthetic schemes for the preparation of radiolabeled probes with unique scaffolds.
Scheme 15: A. Structures of the oxazine-derived fluorescence probes discussed. B. Synthetic scheme for the pre...
Figure 6: Structure of THK-265 (190).
Scheme 16: Synthetic scheme for the preparation of quinoxaline analogue 191.
Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)
- Allison S. Limpert,
- Margrith E. Mattmann and
- Nicholas D. P. Cosford
Beilstein J. Org. Chem. 2013, 9, 717–732, doi:10.3762/bjoc.9.82
- identification of small molecules targeting specific mechanisms of neuronal pathology, including glutamate excitotoxicity, mutant protein aggregation, endoplasmic reticulum (ER) stress, loss of trophic factors, oxidative stress, or neuroinflammation. Herein, we review recent advances in the discovery and
- preclinical characterization of lead compounds that may ultimately provide novel drugs to treat patients suffering from ALS. Keywords: amyotrophic lateral sclerosis (ALS); copper/zinc (Cu-Zn) superoxide dismutase 1 (SOD1); glutamate toxicity; neurodegeneration; oxidative stress; Introduction Amyotrophic
- characterized in ALS, including, but not limited to glutamate toxicity, protein misfolding and aggregation, endoplasmic reticulum (ER) stress, loss of trophic factors, oxidative stress, inflammation, disrupted protein trafficking, and mitochondrial dysfunction [5]. Therapeutic development has been based around
Graphical Abstract
Figure 1: FDA-approved riluzole (1) and other ALS drugs currently in phase III clinical trials (2–6).
Figure 2: Riluzole (left) and prodrugs developed by McDonnell et al. [11].
Figure 3: Neurotransmitters N-acetyl-aspartyl glutamate (NAAG, top) and D-serine (bottom).
Figure 4: Thiopyridazines developed to increase EAAT2 protein levels.
Figure 5: Compounds shown to reduce SOD1 expression.
Figure 6: Families of compounds (named in italics) capable of reducing SOD1-induced cellular toxicity and mut...
Figure 7: Compounds identified by Nowak and co-workers [37] in silico that selectively bind SOD1 over human plasm...
Figure 8: 4-Aminoquinolines developed by Cassel and co-workers [43] for disruption of oligonucleotide/TDP-43 bind...
Figure 9: Cu(II)(atsm), an example of a Cu(II)(btsc) copper complex.
Figure 10: Pharmacological inducers of autophagy.
Figure 11: Compounds used to evaluate the effects of trophic factors on ALS disease progression.
Figure 12: Compounds identified as neuroprotective.
Figure 13: Compounds developed to reduce oxidative stress and inflammation.
Figure 14: Probes used to elucidate the roles of distinct gene-expression profiles in ALS patients.
Figure 15: Targets of potential therapeutics: This diagram illustrates the physiological targets of each compo...
